本研究回顾性比较了成人 T 细胞白血病/淋巴瘤患者的各种同种异体造血细胞移植 (allo-HCT) 平台的结果。平台包括使用移植后环磷酰胺（PTCY）的人类白细胞抗原（HLA）半相合相关供体、HLA 匹配相关供体（MRD）、HLA 匹配无关供体（MUD）和脐带血移植（CBT）。 2016 年至 2021 年间接受首次同种异体 HCT 的患者也被纳入其中。分析的结果是总生存期（OS）、复发死亡率和非复发死亡率（NRM）。纳入了 700 名患者（PTCY，n = 121；MRD，n = 91；MUD，n = 160；CBT，n = 328）。幸存者的中位随访时间为 794 天，2 年 OS 分别为 48.1% (PTCY)、48.8% (MRD)、48.4% (MUD) 和 34.6% (CBT)； 2年累计复发率分别为37.1%、47.5%、33.9%和45.1%，NRM分别为24.2%、19.8%、24.7%和27.3%。相对于 MRD 和 MUD，PTCY 与血小板植入延迟相关。严重急性或慢性移植物抗宿主病的发生率没有增加。在PTCY组中，较差的体能状态是较差OS的重要预测因素，并且输注的CD34细胞数量低于5 × 106/kg与中性粒细胞和血小板植入延迟相关。这些结果表明，对于成人 T 细胞白血病/淋巴瘤患者来说，采用 PTCY 的异基因 HCT 是一个安全有效的平台。© 2024 作者。英国血液学杂志由英国血液学会和约翰·威利出版

This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included. Outcomes analysed were overall survival (OS), relapse and non-relapse mortality (NRM). Seven hundred patients were included (PTCY, n = 121; MRD, n = 91; MUD, n = 160; CBT, n = 328). With a median follow-up of 794 days for survivors, 2-year OS was 48.1% (PTCY), 48.8% (MRD), 48.4% (MUD) and 34.6% (CBT); the respective 2-year cumulative incidence of relapse was 37.1%, 47.5%, 33.9% and 45.1% and that of NRM was 24.2%, 19.8%, 24.7% and 27.3%. PTCY was associated with delayed platelet engraftment relative to MRD and MUD. There was no increase in the incidence of severe acute or chronic graft-versus-host disease. In the PTCY group, poor performance status was a significant predictor of inferior OS, and infused CD34+ cell numbers of less than 5 × 106/kg were associated with delayed neutrophil and platelet engraftment. These results suggest that allo-HCT with PTCY is a safe and effective platform for patients with adult T-cell leukaemia/lymphoma.© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.